spacer
home > ebr > summer 2003 > maximising return on investment with r&d portfolio management
PUBLICATIONS
European Biopharmaceutical Review

Maximising Return on Investment with R&D Portfolio Management

Product prioritisation at a tactical level - identifying the most desirable and attractive products in a company's R&D pipeline - remains the primary focus of portfolio management today. This factor, coupled with the need to maximise return on investment, acts as a strong driving force for pharmaceutical companies to perform portfolio management.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Morten Soegaard, Research Analyst at Frost & Sullivan


Morten Soegaard, a Research Analyst at Frost & Sullivan, has recently finished his analysis on R&D Portfolio Management. As a member of the pharmaceuticals team he previously investigated the European market on commercial opportunities for inhalation drug delivery in diabetes.

spacer
Morten Soegaard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement